Optimum News

Oncolytics Biotech® Inc. and Adlai Nortye Enter into USD $86.6 Million Regional Licensing Agreement for REOLYSIN®

Regional license covers China, Hong Kong, Macau, Singapore, South Korea and Taiwan Oncolytics to receive upfront, licensing fee and milestone payments to support phase 3 registration study of USD $21.2 … Continue reading “Oncolytics Biotech® Inc. and Adlai Nortye Enter into USD $86.6 Million Regional Licensing Agreement for REOLYSIN®”

By Optimum

STORM Therapeutics Strengthens Board with Appointment of Professor Paul Workman, President and CEO of The Institute of Cancer Research

6 November 2017, Cambridge, UK: STORM Therapeutics, the drug discovery company focused on the discovery of small molecule therapies modulating RNA epigenetics, today announced the appointment of Professor Paul Workman … Continue reading “STORM Therapeutics Strengthens Board with Appointment of Professor Paul Workman, President and CEO of The Institute of Cancer Research”

By Optimum

Forendo Pharma nominates world class scientific advisory board and elects Professor Linda Giudice as the Chairperson

Forendo Pharma, a drug development company developing novel oral treatments for endometriosis patients, announces the nomination of its Scientific Advisory Board today. Forendo is developing tissue-specific hormone inhibitors to rebalance … Continue reading “Forendo Pharma nominates world class scientific advisory board and elects Professor Linda Giudice as the Chairperson”

By Forendo Pharma

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...

GET IN TOUCH